Stocks That Hit 52-Week Lows On Monday
During Monday's session, 402 companies made new 52-week lows.
Impel NeuroPharma’s Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, Impel NeuroPharma's (NASDAQ:IMPL) reported sales totaled $2.80 million. Despite a 6.55% increase in earnings, the company posted a loss of $25.20 million.
JonesTrading Initiates Coverage On Impel Pharmaceuticals with Buy Rating, Announces Price Target of $26
JonesTrading analyst Sean Kim initiates coverage on Impel Pharmaceuticals (NASDAQ:IMPL) with a Buy rating and announces Price Target of $26.
Impel Pharmaceuticals: Q2 Earnings Insights
Impel Pharmaceuticals (NASDAQ:IMPL) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell
• Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.
Impel Commences Mid-Stage Autism Spectrum Disorder Study
Impel Pharmaceuticals (NASDAQ: IMPL) has dosed the first patient in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.
Impel NeuroPharma’s Return On Capital Employed Insights
Impel NeuroPharma (NASDAQ:IMPL) brought in sales totaling $1.76 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.0%, resulting in a loss of $26.97 million.